NextCell Pharma invited speaker at the World Advanced Therapies & Regenerative Medicine Congress

NextCell Pharma AB ("NextCell" or the "Company") has compiled questions from the company’s stakeholders in a Q&A section. The questions and answers can be accessed via the link below.

NextCell Pharma AB ("NextCell" or the "Company") today announces that multiple treatments with ProTrans cell therapy does not induce donor specific antibodies in type-1 diabetes patients. A detailed analysis of how the immune system reacts to infusion of ProTrans cells show that treatment can be given to any adult type 1 diabetic, irrespective of pre-existing HLA antibodies.

NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Year-End Report for the period September 1, 2022 – August 31, 2023. The report is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-report. NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period in the previous year.  

NextCell Pharma AB (“NextCell” or “the company”) announces that the company has signed an agreement with the Finnish biotechnology company Linio to warehouse and distribute Tience® in Sweden. The value of the agreement for the first year amounts to approximately 400 000 SEK in fixed remuneration and a variable remuneration per product delivered. Tience is a tissue product that is injected to combat scarring and can also be used for aesthetic purposes such as skin rejuvenation and to combat wrinkles. The product is marketed and sold by Linio to clinics and hospitals.

NextCell Pharma participates in Advanced Therapies Europe, a European conference in Portugal on advanced cell therapies. NextCell's CSO Dr. Lindsay Davies will talk about NextCell's platform technology and the internationally recognized research generated during the development of drug product ProTrans for type 1 diabetes.

Results from Professor Per-Ola Carlsson, Principal Investigator for NextCell’s Phase-I/II study with ProTrans stromal cells for Type 1 Diabetes are now published and featured in the Up-front section of the current issue of Diabetologia. The article was selected by the Editor as worthy of special attention, for its high quality and interest to the diabetes field. Furthermore, the article has already been cited in an International scientific journal.

NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 3 for the period March 1, 2023 – May 31, 2023 The report is available on the company’s website:  https://www.nextcellpharma.com/en/investors#financial-report. NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period in the previous year.  

NextCell Pharma AB ("NextCell" or the "Company") announces that the clinical trial ProTrans 19+SE (also called Protrans V) can start recruiting patients in the high dose group, which is the last dose group. Three patients treated with medium dose of ProTrans have been clinically evaluated and the data has been reviewed by the Data Safety Monitoring Board, which now allows continued treatment with high-dose ProTrans for severe pneumonia caused by COVID-19, Influenza, Human Metapneumovirus and RSV.